DOI:
10.1055/s-00023610
Drug Research
LinksClose Window
References
Poddubnyy D, Hermann KG, Callhoff J et al.
Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS).
Ann Rheum Dis 2014;
73: 817-823
Search in:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.